This site is intended for Healthcare professionals only.

New Nasal Spray for Treating Paroxysmal supraventricular tachycardia


New Nasal Spray for Treating Paroxysmal supraventricular tachycardia

According to a study presented at the annual meeting of the Heart Rhythm Society, held from May 10 to 13 in Chicago, an experimental nasal spray, etripamil, has been found to  benefit patients with paroxysmal supraventricular tachycardia (PSVT),.

The Etripamil spray, was tested in patients with paroxysmal supraventricular tachycardia (PSVT)which  affects about 500,000 Americans and leads to more than 50,000 hospital visits a year in the United States. At present  there is no  definite treatment of PSVT that patients can use at home or without medical supervision. The patients have to report to hospital and get  treated with adenosine, calcium channel blockers or beta blockers, which must be given intraveneously under monitored setting.

“This study introduces a completely novel therapy that has never been used before, and has the potential to alter how we treat patients with PSVT,” said study lead author Dr. Bruce Stambler. He is a cardiac electrophysiologist at Piedmont Heart Institute in Atlanta.

The phase 2 trial included 104 patients from the United States and Canada. The researchers said heart rate was controlled within 15 minutes in 87 percent of patients who received a 70-mg dose of the nasal spray; 75 percent of patients who got 105 mg; and 95 percent of patients given a 140-mg dose. The most common side effects of etripamil were temporary nasal congestion or irritation, according to the researchers.

“This study introduces a completely novel therapy that has never been used before, and has the potential to alter how we treat patients with PSVT,” lead author Bruce Stambler, M.D., a cardiac electrophysiologist at Piedmont Heart Institute in Atlanta, said in a news release from the Heart Rhythm Society. “Many patients who suffer from PSVT can experience sudden episodes anytime and anywhere. This fast-acting nasal spray therapy could give patients the convenience to self-administer treatment no matter the location and without having to go to the hospital.”

Many patients who suffer from PSVT can experience sudden episodes anytime and anywhere. This fast-acting nasal spray therapy could give patients the convenience to self-administer treatment no matter the location and without having to go to the hospital,” Stambler said in a society news release.This is a breakthrough study for domiciliary treatment of PSVT.

Source Milestone Pharmaceuticals Montreal, Canada

Heart Rhythm Scientific Sessions (Heart Rhythm Society)

C-LBCT01-02 / C-LBCT01-02 – Intranasal Etripamil For Conversion Of Paroxysmal Supraventricular Tachycardia (PSVT). Node-1 Trial

The following two tabs change content below.
Anjali Nimesh

Anjali Nimesh

Anjali Nimesh Joined Medical Dialogue as Reporter in 2016. she covers all the medical specialty news in different medical categories. She also covers the Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in medical filed. She is a graduate from Dr. Bhimrao Ambedkar University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Anjali Nimesh

Latest posts by Anjali Nimesh (see all)

Source: self

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted